Vilket är priset för Hugel, Inc. (145020)

Priset för Hugel, Inc. (145020) är $172.53

Vilket är marknadsvärdet för Hugel, Inc. (145020)

Marknadsvärdet för Hugel, Inc. (145020) är $1.86B

Hugel, Inc. (145020) Intäkter

Hugel, Inc. is a biopharmaceutical firm headquartered in Chuncheon-si, South Korea, with a presence both domestically and internationally. The company specializes in the development and manufacturing of diverse medical solutions. A primary product is its Botulinum Toxin, presented as a clear glass vial containing a white, injectable dry powder. This therapeutic is prescribed for several conditions: treating essential eyelid spasms in adults over 18; ameliorating severe frown lines linked to corrugator and/or procerus muscle activity in adults aged 18 to 65; managing upper limb spasticity following a stroke; and correcting dynamic equinus foot deformity in children with cerebral palsy aged over 2. Furthermore, it aids in improving the lateral canthal lines (crow's feet) caused by orbicularis oculi muscle activity in adults between 19 and 65. This product is marketed under various labels, including Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot. Hugel also provides hyaluronic acid dermal fillers, known as Dermalax and The Chaeum; cosmetic products under the Wellage brand; and medical devices distributed as BlueRose. Hugel, Inc. commenced operations in 2001.

År	Intäkter	Ändra
Inte tillräckligt med data för de angivna datumen.

År

Intäkter

Ändra

Inte tillräckligt med data för de angivna datumen.

Företag	Intäkter	Intäktsdifferens	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.74B	-	AU
Moderna, Inc. MRNA.US	$2.23B	-	US
Lonza Group AG LONN.SW	-	-	CH

Företag

Intäkter

Intäktsdifferens

Land